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ABSTRACT The blood-brain barrier (BBB) protects the central nervous system
(CNS) by restricting the passage of molecules and microorganisms. Despite this bar-
rier, however, the fungal pathogen Cryptococcus neoformans invades the brain, caus-
ing a meningoencephalitis that is estimated to kill over 600,000 people annually.
Cryptococcal infection begins in the lung, and experimental evidence suggests that
host phagocytes play a role in subsequent dissemination, although this role remains
ill deﬁned. Additionally, the disparate experimental approaches that have been used
to probe various potential routes of BBB transit make it impossible to assess their
relative contributions, confounding any integrated understanding of cryptococcal
brain entry. Here we used an in vitro model BBB to show that a “Trojan horse”
mechanism contributes signiﬁcantly to fungal barrier crossing and that host factors
regulate this process independently of free fungal transit. We also, for the ﬁrst time,
directly imaged C. neoformans-containing phagocytes crossing the BBB, showing that
they do so via transendothelial pores. Finally, we found that Trojan horse crossing
enables CNS entry of fungal mutants that cannot otherwise traverse the BBB, and
we demonstrate additional intercellular interactions that may contribute to brain en-
try. Our work elucidates the mechanism of cryptococcal brain invasion and offers ap-
proaches to study other neuropathogens.
IMPORTANCE The fungal pathogen Cryptococcus neoformans invades the brain,
causing a meningoencephalitis that kills hundreds of thousands of people each year.
One route that has been proposed for this brain entry is a Trojan horse mechanism,
whereby the fungus crosses the blood-brain barrier (BBB) as a passenger inside host
phagocytes. Although indirect experimental evidence supports this intriguing mech-
anism, it has never been directly visualized. Here we directly image Trojan horse
transit and show that it is regulated independently of free fungal entry, contributes
to cryptococcal BBB crossing, and allows mutant fungi that cannot enter alone to in-
vade the brain.
Fungal infections of the central nervous system (CNS) cause 1.5 million deaths everyyear worldwide (1). The major cause is the basidiomycete Cryptococcus neoformans
(2), a ubiquitous environmental yeast (3, 4). Inhalation of this pathogen leads to
pneumonia, which in healthy people either is resolved or remains asymptomatic. In the
setting of immunocompromise, however, C. neoformans disseminates, with speciﬁc
tropism for the CNS. To enter the brain, C. neoformans must cross the blood-brain
barrier (BBB), which protects the CNS from chemical and infectious damage (5).
Potential routes of cryptococcal entry include (i) direct fungal interactions with brain
endothelial cells, leading to endocytosis and subsequent transcytosis of free fungi
(6–9); (ii) disruption of BBB endothelial cell junctions, allowing paracellular passage of
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free fungi (10–13); and (iii) “Trojan horse” crossing, where fungi traverse the BBB within
infected phagocytes (14–17), either transcellularly or paracellularly. However, whether
all of these routes are used, the mechanistic details of the routes, and their relative
contributions to brain infection are not known.
Evidence that C. neoformans uses a Trojan horse mechanism to traverse the BBB is
primarily derived from indirect studies in vivo, including histological observation of
fungi within phagocytes in brain microvasculature and parenchyma (18) and adoptive
transfer experiments using infected macrophages (14, 16). In the adoptive transfer
studies, intravenous (i.v.) administration of infected macrophages increased brain
burden compared to infection with free cryptococci (14, 16). These experiments
strongly suggest that phagocyte association provides a dissemination advantage,
which could occur either upstream of CNS entry or at the point of BBB traversal.
However, interpretation of these studies is complicated by the long intervals between
infection and brain harvest, particularly because cryptococci grow both inside and
outside host cells and can move between the two compartments while maintaining
viability. Interpretation was also complicated in adoptive transfer studies where a
heterologous population of macrophages, including free, adherent, and internalized
cryptococci, was introduced into mice; in vivo, there is no way to track which popula-
tion of fungi leads to the observed brain burden, so the route of BBB crossing cannot
be determined.
Recently, the Trojan horse pathway was examined in vitro using a mixture of fungi
and monocytes (including free, adherent, and internalized fungi) and a Transwell BBB
model. At one day after addition of this mixture, monocytes containing fungi were
observed in the lower chamber, suggesting that Trojan horse crossing had occurred
(17). As with the earlier in vivo experiments, however, the mixed population and the
potential for a long incubation to allow multiple cellular interactions (e.g., exit from
phagocytes, free fungal crossing, and reuptake in the lower chamber) make it difﬁcult
to reach a deﬁnitive conclusion about the occurrence of Trojan horse transit in these
studies.
Here we combined ﬂow cytometry, ﬂuorescent and live-cell microscopy, and several
BBB models to directly demonstrate Trojan horse crossing. We further showed that it
occurs via transcellular pore formation, is regulated independently of free fungal entry,
and allows mutant fungi that cannot cross alone to invade the brain. Our results
conclusively demonstrate the ability of C. neoformans to exploit human phagocytes as
Trojan horses, contribute signiﬁcantly to our knowledge of cryptococcal brain entry,
and break new ground in the area of BBB transmigration of pathogens.
RESULTS
Isolation of macrophages loaded with single fungi. To rigorously compare the
BBB passage of free fungi to that of internalized fungi, we modiﬁed a ﬂow cytometry
strategy for the isolation of C. neoformans-infected phagocytes (19), using C. neofor-
mans strain KN99 and cells of the human monocytic cell line THP-1 (THP). After
incubating mCherry-expressing KN99 (see Materials and Methods) with DFFDA-
stained THPs, we applied a sorting strategy (Fig. 1A; see also Fig. S1 in the supplemental
material) that additionally used SYTOX red as a host cell viability marker and calcoﬂuor
white (CFW) as an impermeant stain to identify externally associated fungi. This allowed
us to routinely isolate the desired loaded macrophage population, consisting of healthy
host cells, devoid of externally adherent or free fungi (Fig. 1A; box 1), with a count of
one yeast per cell on average (Fig. S1A). This population is shown in Fig. 1B (panel 1)
and is compared to populations of phagocytes with externally adherent fungi stained
by CFW (Fig. 1A; box 2; Fig. 1B, panel 2) and phagocytes with compromised viability
stained by SYTOX red (Fig. 1A; box 3; Fig. 1B, panel 3).
BBB transit of free fungi and loaded macrophages. In vitro models of the BBB
have previously been used to study transit of free cryptococci (20, 21). We generated
model BBB (BBBM) by seeding the human cerebral microvascular endothelial cell line
hCMEC/D3 (22, 23) on top of permeable inserts in transwell plates (Fig. 1C). We
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FIG 1 Isolation of loaded macrophages and crossing of the BBB by C. neoformans. (A) Final phase of the
sorting strategy used to isolate phagocytes that were healthy (negative for SYTOX dye) and devoid of
external fungi (negative for CFW); the complete strategy is shown in Fig. S1. The boxes corresponding
to the gates are labeled as follows: gate 1, healthy phagocytes with only internal fungi; gate 2, healthy
phagocytes that have external fungi (with or without internal fungi); gate 3, dead or damaged phago-
cytes. Results are representative of results of 69 independent analyses. (B) Cells collected from the gates
shown in panel A (all shown at the same scale; bar  10 m). Images are representative of results of 4
independent sorting studies where cells were examined microscopically. (C) Diagram of the BBB model
used in this study. (D) Transit of free S. cerevisiae (S. cer) or C. neoformans (C. neo) in the absence or
presence of serum; means and standard deviations (SD) of results are shown for one of two similar
studies. (E) Mean and SD values over time for transit (bars, left axis) and TEER (points, right axis), for
various starting inocula of opsonized C. neoformans. Stars represent TEER values at 0 h. Results from one
of two similar studies are shown. (F) Time-dependent transmigration of free fungi, a 1:1 mix of free fungi
and empty THPs, and fungus-loaded THPs (1 to 1.49 fungi/host cell). Means and standard errors of the
means (SEM) are shown for results of one of seven similar independent experiments. Values plotted for
all time course transit assays are cumulative values.
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monitored barrier development and integrity by measuring transendothelial electrical
resistance (TEER) across the monolayer; once it had stabilized (5 to 6 days), we added
particles of interest to the top chamber (representing the blood side of the BBB) and
monitored transmigration by assaying samples from the lower chamber (representing
the brain side) for CFU. Free C. neoformans crossed the BBBM in a time-dependent
manner, consistent with earlier results (20, 21); this was enhanced by the presence of
human serum, suggesting that both opsonin-dependent and opsonin-independent
mechanisms contribute to this process (Fig. 1D). In contrast, Saccharomyces cerevisiae,
despite its similar size and shape, showed minimal traversal that was not inﬂuenced by
serum.
We observed the highest percentage of transmigration in our assays at a fungus/
host cell ratio of ~6 (Fig. 1E; 106 fungi), which is the ratio that we used for subsequent
studies. Higher levels of inocula did not increase this value, suggesting the presence of
a saturable receptor or other limiting host factor. Barrier integrity was maintained over
time with all inocula tested, as shown by constant TEER values (Fig. 1E, right axis). This
suggests a minor role for paracellular traversal due to BBBM compromise; instead, free
fungi probably cross primarily via a transcellular process (see below).
We next compared the levels of transmigration of free serum-opsonized cryptococci
and equal numbers of cryptococci contained within phagocytes; as a control to ensure
that the phagocytes alone did not perturb the barrier, we assayed the same number of
free fungi mixed 1:1 with uninfected phagocytes immediately prior to assay. Under
standard conditions, ~10-fold more opsonized C. neoformans fungi crossed free than
internalized in macrophages (Fig. 1F) (P  0.001). Interestingly, adding empty macro-
phages (“C. neo  THPs”) inhibited traversal of free fungi (P  0.001). This may reﬂect
competition for free fungi between endothelial cells, characterized by low rates of
endocytosis (22), and professional phagocytes (THPs). During the assay, the latter might
have engulfed most of the free fungi, preventing them from interacting with endothe-
lial cells to initiate transcellular crossing and yielding a traversal rate similar to that of
the loaded macrophages.
Direct visualization of Trojan horses associated with model BBB. Previous
studies of Trojan horse crossing have been limited by the use of mixed cell populations
and the lack of evidence that fungi were maintained within host phagocytes during
actual barrier traversal. Our isolation of loaded macrophages devoid of externally
associated cells or free fungi addressed the ﬁrst concern, and we turned to direct
imaging to address the second. We performed 18-h assays with loaded macrophages
and imaged both sides of the cell culture inserts (Fig. 2A). Confocal microscopy of the
top revealed an endothelial cell layer with abundant associated loaded macrophages
(Fig. 2B, top row, and 2C, left). We also observed loaded macrophages associated with
the bottom (“brain” side) of the permeable membranes (Fig. 2B, bottom row, and 2C,
right). Because free C. neoformans fungi do not associate with the cell-free bottom
surface of the membrane, the fungi in these macrophages must have crossed the
barrier within them, thus directly demonstrating Trojan horse crossing. Movie S1 shows
consecutive confocal sections of a ﬁeld with loaded macrophages on both sides of the
membrane.
Physiological inﬂuences on BBBM transit. Cryptococcal meningitis outcome cor-
relates with the levels of immune mediators (24–26). MCP-1 (monocyte chemoattrac-
tant protein-1) and fMLP (N-formyl-methionine-leucyl-phenylalanine) are two chemo-
kines that have been speciﬁcally studied for their roles in cryptococcal infection (27–30).
MCP-1, found at high levels in the brains of cryptococcal meningitis patients (24–26,
31), recruits monocytes to sites of infection and is a critical factor in the immune
response against pulmonary cryptococcosis. Formylated peptides such as fMLP are also
macrophage activators and are potent chemoattractants for phagocytes; these include
neutrophils and dendritic cells, which help control cryptococcal infection (32). Physio-
logical levels of both MCP-1 and fMLP signiﬁcantly stimulated the transit of loaded
macrophages, consistent with their chemoattractant function in vivo; neither inﬂuenced
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the movement of free fungi (Fig. 3A and B). We next tested inositol, which has been
shown to promote the transmigration of free C. neoformans across a model BBB (33).
The presence of inositol at 1 mM, close to the physiological levels in the brain, increased
the transit of free fungi but had no effect on the migration of loaded macrophages
(Fig. 3C). Importantly, none of these regulatory molecules impaired BBBM integrity (not
shown). Together, these studies showed that Trojan horse and free fungal crossing are
independently regulated.
Th1 cytokines, including tumor necrosis factor alpha (TNF-), are critical for protec-
tive immunity and clearance of cryptococcal infection in mice (34). TNF- and type I
interferons (IFNs), such as IFN-, have been implicated in the control of cryptococcal
meningitis in mice and humans (24, 35). These mediators also regulate BBB permea-
bility, especially in response to viral infections (36, 37): TNF- increases barrier perme-
ability, while IFN- decreases it. Adding TNF- or IFN- to our assays, at levels
comparable to those seen in HIV-positive (HIV) patients with cryptococcal meningitis
(24–26), yielded small but signiﬁcant changes in barrier permeability (Fig. 3F and G),
consistent with those reports. TNF-, which increases barrier permeability, also in-
creased the migration of loaded macrophages (Fig. 3D). IFN-, however, did not affect
loaded macrophage migration, possibly because the tightening of the barrier was only
transient (Fig. 3G). With free fungi, both TNF- and IFN- stimulated transmigration
(Fig. 3E), suggesting that these molecules regulate factors beyond barrier permeability
that inﬂuence free fungal transit.
Trojan horses enable BBBM transit by fungal mutants that cannot cross alone.
The CPS1 gene encodes hyaluronic acid (HA) synthase. HA has been implicated in
fungal binding to the CD44 surface receptor on hCMECs, which triggers endocytosis
and subsequent barrier traversal via a transcellular mechanism (8, 38) (Fig. 4A, left).
Consistent with these reports, cps1Δ cells had a profound defect in free fungal BBBM
crossing (Fig. 4B, red-shaded bars). When these mutants were passengers inside Trojan
FIG 2 Visualization of Trojan horse crossing. (A) Experimental design for visualization of both sides of the
permeable membrane. (B) A ﬁeld of view showing loaded macrophages associated with the endothelial
monolayer (top row) and the bottom of the porous membrane with loaded macrophages alone (bottom
row). Both mammalian cell types were stained with CellMask plasma membrane dye (blue); THPs were
further stained with DFFDA from the ﬂow sorting (green) and contained mCherry-stained fungi (red).
Scale bar, 10 m. (C) Merged images from a larger ﬁeld of view, again showing all cell types on the top
of the membrane (left), whereas only loaded phagocytes are visible on the bottom (right). Scale bar,
20 m. Images are representative of multiple ﬁelds from two independent experiments, each with three
independent time points. The ﬁelds shown are from a 1-h time point. We observed loaded macrophages
associated with the bottom of the membrane most frequently early in the incubation period (more at 1 h
than at 2 to 3 h; not shown); this may represent a time-dependent loss of phagocyte viability or ability
to initiate transit. See Movie S1 for another example.
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FIG 3 Differential regulation of free and internalized fungal crossing by immune mediators. (A to C) Transmigration
of free and internalized fungi in the presence of various chemoattractants, with matched controls. (A) fMLP,
N-formyl-methionine-leucyl-phenylalanine peptide (100 nM). DMSO, dimethyl sulfoxide. *, P  0.0001 (by Sidak’s
multiple-comparison test). (B) MCP-1 (also known as CCL2), monocyte chemoattractant protein-1 (100 ng/ml). *,
P  0.03 (by Sidak’s multiple-comparison test). (C) INO, inositol (1 mM). *, P  0.05 (by Sidak’s multiple-comparison
test). (D and E) Transmigration assays using BBB pretreated with TNF- (10 ng/ml) or IFN- (1 ng/ml) for 24 h before
addition of loaded THPs (*, P  0.0003 [for comparisons between TNF- and other treatments by Tukey’s
multiple-comparison test]) (D) or of free fungi (*, P  0.0001 [for comparisons between each compound and PBS
by Tukey’s multiple-comparison test]) (E). (F and G) TEER values of model BBBs treated with 10 ng/ml TNF- (F) or
1 ng/ml IFN- (G) for 24 h prior to initiation of the study (t  0 h), at which point the medium was replaced with
fresh medium without cytokines (*, P  0.01; #, P  0.0002 [all compared to PBS at the same time point by
Dunnett’s multiple-comparison test]).
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horse macrophages, however, they traversed the BBBM as efﬁciently as wild-type fungi
(Fig. 4B, blue-shaded bars). The enzyme urease, encoded by URE1, is also required for
efﬁcient C. neoformans brain invasion in vivo (11, 12). The mechanism in this case is
postulated to be its conversion of urea to ammonia, which could weaken BBB junctions
locally and thereby facilitate paracellular crossing (Fig. 4A, right). We indeed observed
a defect in free fungal crossing of ure1Δ cells (Fig. 4C), although only at late time points,
consistent with previous in vivo results (39). Notably, TEER values remained stable
FIG 4 Loaded macrophages provide an alternative route for mutant cryptococci to gain access into the
brain. (A) The roles of Cps1 and Ure1 in BBB crossing. HA (green ovals on the surface of the fungi [red])
made by Cps1 is recognized by the endothelial cell (EC) surface receptor CD44 (blue shapes), which
triggers endocytosis of the fungal cells. The accumulation of ammonia generated by Ure1 may damage
cellular junction proteins, facilitating fungal brain entry. (B and C) Transmigration of free or internalized
fungi, comparing wild-type and either cps1Δ (B), or ure1Δ (C) mutants. Means plus SEM are plotted. *
denotes P  0.002 and P  0.0001 in panels B and C, respectively (both determined by Sidak’s
multiple-comparison test).
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throughout this experiment (not shown), indicating that the barrier as a whole main-
tained integrity; it may be that the time-dependent accumulation of ammonia acts only
locally or that the monolayer, if disrupted, is perturbed only transiently and recovers
rapidly. Again, the mutation did not inhibit the transmigration of internalized fungi
(Fig. 4C), conﬁrming that even mutants that are deﬁcient in free fungal entry into the
brain can still exploit the Trojan horse route of transit across the BBB. In both studies,
some free fungal crossing still occurred with mutant cells, likely due to the multiple
possible mechanisms by which free fungi may traverse the BBB (Fig. 4A).
Trojan horse phagocytes convey cryptococci across transcellular pores. Our
confocal microscopy analysis (Fig. 2) provided direct evidence for a Trojan horse
mechanism of BBB traversal, in contrast to prior indirect evidence for such transit of a
variety of pathogens (40–45). To observe cryptococcal transit over time and to obtain
mechanistic insights, we used live-cell microscopy. We ﬁrst seeded hCMECs on
collagen-coated polyacrylamide (PA) hydrogels, which reproduce the physical proper-
ties of in vivo tissues (46), and monitored the monolayers by phase-contrast microscopy
to conﬁrm formation of a single, uninterrupted layer with uniform junctions (Fig. 5A);
transmission electron microscopy (TEM) also showed a thin cell monolayer with mini-
mal cytosolic overlap and well-developed junctions (Fig. S2A). To observe intercellular
interactions, we then added primary human monocytes loaded with C. neoformans (see
Materials and Methods) and acquired images every minute for 6 to 16 h. These cells
interacted with the endothelial layer more actively than loaded THP-1 cells, with 36%
of 60 total events recorded showing Trojan horse transmigration. The typical pattern of
Trojan horse crossing that we observed is shown in Fig. 5B and C (images extracted
from Movies S2 and S3, respectively). The ﬁrst image (panel 1) in each sequence shows
a loaded monocyte associated with the endothelial cell layer. Host membranes then
extend around the loaded phagocyte (panel 2, arrows), a process that follows extensive
membrane activity at that site (see Movies S2 and S3) and leads to formation of a
transcellular pore (47) (panel 3). After transmigration of the Trojan horse through the
pore and pore closure, the fungi can still be seen through the endothelial cell (panel 4),
but with a marked loss of refractility compared to the early images. These fungi
remained within the original phagocytic cell throughout the process (better visualized
in the single-color channels of the movies).
To observe transmigration events at higher resolution, we prepared samples as
described for the video microscopy, incubated the samples for 6 h, washed the samples
extensively to remove nonassociated loaded monocytes and media components, and
ﬁxed the samples for transmission electron microscopy (TEM). Consistent with the
lengthy association between phagocytes and endothelial cells that precedes the rapid
progression of transmigration shown in our videos, our TEM images included numerous
examples of loaded phagocytes interacting with the endothelial cell monolayer
(Fig. S2B) and only occasional instances of transmigration events in progress. One of the
latter (Fig. 5D) demonstrates the partial progress of a monocyte, which carries a
budding cryptococcal cell, through a transcellular pore. TEM also showed free crypto-
coccal cells within brain endothelial cells, presumably in the process of transcytosis
(Fig. S2C).
We performed similar live-cell studies of loaded THPs and observed various known
behaviors of intracellular C. neoformans, including intracellular proliferation (not
shown), lytic exocytosis (Movie S4, left side), and nonlytic exocytosis (Movie S4, right
side) (48). We also observed several instances of cell-to-cell transmission of fungal cells,
which has been reported to occur between macrophages (49, 50). In our studies, the
fungal movement was from phagocytic to endothelial cells (Movie S5), a novel ﬁnding.
Free fungi in our movies, probably arising from lytic or nonlytic exit from the loaded
macrophages, sometimes associated with or were internalized by endothelial cells, in
one case subsequently replicating and then being expelled (Movie S6).
In 10% of the traversal events that we observed, the fungal cargo appeared to
impede monocyte transit across the endothelial cell layer, with the portion of the host
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cell containing the fungi apparently stuck on the luminal side for the duration of the
movie (Movie S7, red arrow). To assess the potential interference with monocyte transit
and possible speciﬁcity of this process, we compared the transit of empty THPs to that
of THPs loaded with either C. neoformans or S. cerevisiae (Fig. S3A). These studies, whose
results we analyzed by both measuring ﬂuorescence (Fig. S3B) and directly imaging and
counting cells in the lower chamber (Fig. S3C), suggested that the presence of either
yeast slightly inhibited host cell transmigration; there was no difference between the
two fungal species in this regard.
DISCUSSION
Because C. neoformans thrives intracellularly, the idea of the use of a Trojan horse
model for its dissemination to the CNS has been historically appealing and is supported
FIG 5 Visualization of Trojan horse crossing by real-time and electron microscopy. (A) hCMEC monolayers
were grown on glass or 0.4% PA pads were grown to conﬂuence and ﬁxed, and adherens junctions were
stained with anti-VE-cadherin antibody. Nuclei were stained with propidium iodide. (B and C) Two examples
of loaded primary human monocytes crossing endothelia, from Movie S2 (B) and Movie S3 (C); see text for
details. (D) TEM of a loaded monocyte in the process of transendothelial migration (left), with a corre-
sponding drawing to identify structures (right). N, nucleus; V, vacuole; F, fungal cell; B, brain endothelial cell.
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by a variety of indirect studies. However, conﬁrming Trojan horse transit has posed
signiﬁcant experimental challenges, despite its importance for understanding how
C. neoformans and related species colonize the brain (17, 51, 52). Here we show for the
ﬁrst time that cryptococcal cells maintained within phagocytes cross brain microendo-
thelial barriers, directly demonstrating Trojan horse transit.
Our comparisons of the transit of free fungi to that of phagocytes with internalized
yeast showed that free fungi crossed our model BBB more efﬁciently. However, these
in vitro studies likely underestimate the role of Trojan horse transit in vivo for several
reasons. First, free C. neoformans does not survive well in serum and is rapidly cleared
from the bloodstream following i.v. inoculation in mice (53, 54). Second, unlike free
cryptococci, phagocytic cells stick, albeit transiently, to the bottom of the membrane as
they cross a model BBB. Although this allowed us to directly demonstrate the transit of
loaded macrophages, it likely leads to an underestimation of the internal fungi when
the medium in the lower chamber is sampled, as in our assays. In addition, we found
that host signals relevant to infection differentially regulate the crossings of free and
internalized fungi; these factors may cause greater levels of Trojan horse crossing
during infection in vivo than we detected in vitro. Finally, it has been suggested that
free fungi adherent to the luminal side of brain microvasculature may be removed by
neutrophils (55), a process that would reduce their transit but would not occur in our
system.
The balance of routes used by C. neoformans to enter the brain may change during
the course of infection. This could be mediated in part by changing levels of host
immune regulators, which modulate BBB crossing. These regulators may be inﬂuenced
by characteristics of the infecting strain of C. neoformans, such as the release of the
polysaccharide capsule, a major virulence factor. For example, the level of MCP-1, which
we found speciﬁcally stimulated Trojan horse crossing, is decreased in infections
with strains shedding small amounts of capsule compared to strains shedding
intermediate levels. Similarly, high levels of TNF-, which stimulated both Trojan
horse and free fungus traversal, correlate with infecting strains that have high levels of
capsule shedding (4). The balance of routes could also be inﬂuenced by the progression
of the disease itself. In our work, the greatest speciﬁc effect on Trojan horse traversal
was caused by fMLP. Formyl peptides such as fMLP stimulate not only leukocyte
chemotaxis but also degranulation, superoxide production, and activation of integrins
for cell adhesion, all of which promote inﬂammation. Both in vivo and in vitro studies
have suggested that endothelial damage occurs late in cryptococcal infection (13, 54).
Such damage would result in release of formyl peptides, again potentially shifting the
balance of CNS entry routes.
Our live-cell microscopy of Trojan horse crossing showed a distinctive sequence of
events (Fig. 5). These events are consistent with the process of transendothelial pore
formation, cartooned in Fig. 6, where the phagocyte (green) essentially crosses through
a “donut hole” that forms in the endothelial cell, without ever entering its cytosol. This
mechanism has not been considered in the cryptococcal literature, although it is
consistent with models for inﬂammatory cell crossing in the brain. Due to the presence
of extremely tight junctions in brain endothelia, transendothelial pore transit accounts
for up to 90% of cellular crossing of the BBB, in contrast to other endothelia, where
most crossing occurs paracellularly (56). A minor role for paracellular transit is consis-
tent with the stable TEER values measured during our assays. It is also consistent with
our observations revealing that, in several videos where cell boundaries are clear,
crossing occurred at the cell body rather than at the edges (Movies S2 and S3 and data
not shown). While it is conceivable that a particle could cross the endothelial barrier
without perturbing TEER (if the apical junction sealed before the basal one was
breached), we consider this unlikely because of the kinetics of crossing and the large
size of the fungus relative to the thickness of the endothelial layer (Fig. S2C).
We also recorded other behaviors that could contribute to C. neoformans BBB
crossing. These included nonlytic escape from phagocytes and a novel process of
fungal movement from phagocytes directly into endothelial cells; both of these suggest
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additional modes of BBB traversal where phagocytes participate without acting as
Trojan horses. For example, phagocytes could bring cryptococci to the BBB, where they
would either exit and cross transcellularly on their own or be delivered directly into the
endothelia by cell-to-cell transfer (Fig. 6B and Movies S4 and S5). Although Trojan horse
crossing was more frequent (36% of recorded events) than nonlytic exocytosis or direct
transfer (26% or 3%, respectively) in our system, the latter mechanisms may contribute
to brain entry in vivo (19, 57).
The presence of internalized fungi, whether C. neoformans or model yeast, had a
modest inhibitory effect on phagocyte traversal (Fig. S3). Our movies suggest that this
may be because they contain relatively large and rigid structures that are not easily
accommodated by the endothelial pore; this idea is also supported by a correlation
between this inhibition and the number of internalized fungi per cell (not shown). The
effect of the physical parameters of the yeast is also evident in our TEM observations
of free fungal transit. The thin brain endothelium is dramatically distorted by fungal
entry, such that the yeast contacts both cell surfaces (Fig. S2C). The long ﬁbers
surrounding the internalized cryptococci are presumably cytoskeletal elements, which
FIG 6 Mechanisms of brain infection by C. neoformans. (A) Depicted are wild-type fungi (red ovals)
crossing the BBB either free (1) or within Trojan horse phagocytes (2). Mutant fungi (orange ovals) cannot
cross alone (3) but can use Trojan horse transit as an alternative route. See text for details on
transendothelial pore formation for Trojan horse transit. (B) Loaded phagocytes potentially contribute to
brain invasion by pathways that do not involve true Trojan horse transit (2). Phagocytes can bring the
fungus to the CNS internally and then exit the phagocyte by nonlytic exocytosis and cross the BBB as free
yeast by transcytosis (1). Finally, we observed two instances of direct cell-to-cell transfer of fungal cells
from phagocytes to endothelial cells (3), supporting the hypothesis of a “taxi” mechanism, where loaded
phagocytes deliver fungal cells directly into brain endothelial cells. Pink, blood vessel lumen; pale green,
brain parenchyma; blue cells, brain endothelial cells; green cells, infected phagocytes; shaded gray
rectangle, the extracellular matrix that forms the BBB basal membrane.
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could potentially trigger expulsive events toward either side, such as those shown in
Movie S6, where the fungal cell is internalized by and subsequently exits from the same
face of the endothelial layer.
We found that fungal cells that cannot cross the BBB on their own (Fig. 6, orange
ovals) can still reach the brain inside phagocytes, at levels comparable to those seen
with normal fungi. This is likely to be relevant to pathogenesis, as exempliﬁed by
mutants lacking Cps1, which produces a ligand for endothelial cell CD44 (Fig. 4A).
Although independent transmigration of these mutant fungi is reduced ~50% com-
pared to that of wild-type fungi in vitro, wild-type infections of CD44/ mice show a
smaller reduction in brain burden and a minimal effect on virulence (58). This can be
explained by a model where most circulating fungal cells are inside phagocytes. These
fungi would not need the CD44 interaction to efﬁciently cross the BBB, consistent with
the in vivo observations and supporting the idea of a role for Trojan horse crossing in
vivo. These ﬁndings highlight the need to consider internalized fungi in assessments of
antifungal agents and the potential value of identifying compounds that inhibit
intracellular replication of cryptococci, as in a recent screen (59).
Any intracellular pathogen that can survive within phagocytes can potentially
exploit them as Trojan horses for dissemination or delivery into target organs, although
some may use other mechanisms, as suggested recently for Toxoplasma gondii (60). Our
work shows the importance of dissecting these mechanisms for C. neoformans and
other neuropathogens and provides methods and approaches for doing so.
MATERIALS AND METHODS
Mammalian cells and growth conditions. The human monocytic cell line THP-1 (TIB-202, from the
ATCC) was cultured and differentiated as described in reference 61. These cells were negative for
mycoplasma. For the model BBB, we obtained the immortalized human brain endothelial cell line
hCMEC/D3, described and reviewed in reference 22. These cells were obtained from Babette Weksler
(Cornell University Medical College) and were grown as described in reference 23. Primary blood
monocytes were isolated by negative immunoselection (Pan Monocyte isolation kit; Miltenyi Biotec, Inc.)
from peripheral blood mononuclear cells (PBMCs) that were obtained from leukoreduction (LRS) cham-
bers following routine platelet donations at the apheresis center at Washington University School of
Medicine. The cells were kept in suspension by growth in ultra-low-adherence ﬂasks (Corning) in human
peripheral blood monocyte (hPBM) medium (RPMI medium with L-glutamine and sodium bicarbonate,
10% fetal bovine serum [FBS], 1 mM sodium pyruvate, 1 penicillin-streptomycin [PenStrep], 1%
nonessential amino acids [NEAA], and 10 mM HEPES [pH 7]).
Fungal strains. Most studies used C. neoformans strain KN99 (62), provided by Joe Heitman, or
mCherry-expressing KN99 from Jennifer Lodge and Raj Upadhya. A ure1Δ strain in the KN99 back-
ground was from the 2015 Madhani partial-deletion collection (Fungal Genetics Stock Center, University
of Missouri—Kansas City, Kansas City, MO). A cps1Δ strain in the H99 background was obtained from
an earlier Madhani collection (63); H99 was used as a control for experiments performed with this
mutant. S. cerevisiae strain BY4741 (64), provided by Michael Brent, was transformed with an integrative
plasmid expressing cytoplasmic mCherry (from Addgene).
Fungal uptake by phagocytes. THPs seeded at 1.67  105 cells/ml and grown in T175 ﬂasks were
labeled with 1 M DFFDA succinimidyl ester (DFFDA-SE) (CellTrace Oregon Green; Thermo Fisher
Scientiﬁc) and challenged with mCherry-expressing fungi or fungi stained with 15 M DDAO-SE
(CellTrace Far Red; Thermo Fisher Scientiﬁc) at a multiplicity of infection (MOI) of 3. A 2.5-h incubation
at this MOI yielded close to 1 yeast per host cell (Fig. S1A), with more than half of the THPs infected and
relatively few externally adherent fungi (Fig. S1B). For some uptake studies, fungi were opsonized (30 min
at 37°C with rotation) with 40% fresh serum (from healthy individuals at the Washington University
School of Medicine; Institutional Review Board [IRB] 201101914) before being exposed to phagocytes.
After 2.5 h, ﬂasks were washed twice with 2 mM EDTA–phosphate-buffered saline (PBS) to remove free
and loosely adherent fungi and the THPs were detached with Cellstripper (Corning), a nonenzymatic cell
dissociation solution. The cells were then washed once with medium lacking phenol red and resus-
pended in Presort buffer (BD Biosciences) with 10 g/ml calcoﬂuor white (CFW) to stain external fungi
and 5 nM SYTOX red (using mCherry-expressing fungi) or SYTOX orange (using DDAO-stained fungi) as
a host cell viability dye. A similar approach was used with primary blood monocytes (not shown), except
that initial washes were done by centrifugation and uptake was performed in medium without phenol
red at an MOI of 1 for at least 3 h; infected cells were then sedimented and resuspended in Presort buffer
containing CFW and SYTOX red as described above.
Flow cytometry. To optimize phagocytosis assays, we analyzed uptake reactions on an LSRII
instrument (BD Biosciences). Cell sorting was performed on a FACSAria II system (BD Biosciences)
following standard procedures with appropriate precautions for a biosafety level 2-plus (BSL-2) organ-
ism. The gating strategy is shown in Fig. S1C to F (and the last step only is shown in Fig. 1A); at least 106
cells were routinely collected from gate 1 in Fig. 1A and Fig. S1F. All results were analyzed and formatted
for presentation using FlowJo software (Treestar).
Santiago-Tirado et al. ®















In vitro BBB. BBBM (Fig. 1C) examples were generated as described in reference 23 with some
modiﬁcations. Brieﬂy, hCMEC/D3 were seeded at 5  104 cells/cm2 (for 0.9-cm2 permeable inserts) or
6  104 cells/cm2 (for 0.33-cm2 inserts) on the apical side of 8-m-porosity inserts (BD Falcon, Corning)
that had been coated with 150 g/ml Cultrex rat collagen I (R&D Systems) for at least 1 h at 37°C prior
to washing with PBS and adding the cells. The cells were grown for 4 to 5 days in EBM2 (Lonza)
supplemented with FBS (5%), penicillin-streptomycin (1%), hydrocortisone (1.4 M), ascorbic acid
(5 g/ml), chemically deﬁned lipid concentrate (1%), HEPES (10 mM), basic ﬁbroblast growth factor
(bFGF) (1 ng/ml), and human vascular endothelial growth factor (hVEGF) (2 ng/ml). At 24 h prior to the
assays (when the monolayer was already conﬂuent), the medium was replaced with differentiation
medium (as described above but with 1% FBS and no growth factors). TEER was measured with an
EVOM2 (WPI) with either an STX2 electrode (for 12-well plates) or an STX100 electrode (for 24-well
plates). We routinely achieved values of ~80  · cm2 for 0.9-cm2 inserts and ~60  · cm2 for 0.33-cm2
inserts with 8-m-pore-size membranes. We observed much lower TEER values when we used inserts
with 0.4-m pores (not shown). These results were similar to what was found in a recent study, although
even those barriers were reported to still maintain integrity with respect to large molecules (65).
Transendothelial migration assays. For studies with free fungi, log-phase C. neoformans fungi were
washed twice in PBS and 108 cells were resuspended and incubated in 40% fresh human serum–PBS for
30 min at 37°C. The cells were collected by centrifugation and resuspended at 2  106 cells/ml in
migration media (RPMI medium containing 1% FBS), and 500 l of the suspension was added to the top
of a permeable insert (usually 0.9-cm2 permeable inserts in 12-well plates), which was then moved into
a new plate with 1.5 ml of migration medium/well. At each time point, TEER was measured. Inserts were
then moved to new plates with prewarmed migration medium, and aliquots of the prior lower chamber
were spotted on yeast extract-peptone-dextrose (YPD) plates for CFU quantiﬁcation. For studies involv-
ing loaded macrophages, 105 particles (free fungi, loaded macrophages, or a 1:1 mix of free fungi and
empty macrophages)–300 l of migration media was added to the top of a 0.33-cm2 Corning HTS insert
(in a ﬁxed-format 24-well plate to allow plate centrifugation without cross-contamination). Prior to each
sampling, the plate was subjected to centrifugation (1,000 rpm, 5 min, 37°C) and the insert assembly was
moved to a new plate containing 1 ml migration medium/well; aliquots from the prior wells were spotted
on YPD plates for CFU quantiﬁcation. In some studies, chemoattractants or cytokines were present in the
bottom chamber of each well at the concentrations noted in the text. Excluding Fig. 1, all experiments
incorporated 4 technical replicates for each condition tested. This allowed experiments to be performed
in individual multiwell plates, eliminating plate-to-plate variation for this complex system. Each exper-
iment was performed at least twice independently, with similar results; one example is shown. Details of
replicates prepared as described for Fig. 1 are provided in the corresponding legend.
Direct visualization of insert membranes. BBB transit assays were performed as described above,
the inserts were removed from 12-well plates and immersed twice in HBSS (Hanks balanced salt
solution containing 1% glutamine, 1% PenStrep, 140 mg/liter CaCl2, 100 mg/liter MgCl2, 100 mg/liter
MgSO4, and without phenol red), after which both sides were ﬁxed with 4% formaldehyde–PBS (10 min,
room temperature [RT]). The ﬁxed inserts were washed in HBBS twice and both sides stained with
CellMask Deep Red Plasma membrane stain (Thermo Fisher Scientiﬁc) (1:10,000 in PBS; 10 min, RT) and
washed twice in HBBS. The inserts were then excised from the plastic housing using 10-mm-diameter
skin biopsy specimen punches and placed monolayer side up on a bubble of mounting media on a
microscope slide. Another few microliters of mounting media and a coverslip were then applied. After
the mounting media had cured, the membrane was viewed on a Zeiss LSM 510 confocal laser scanning
system. To image cells directly, we used Fluoroblok plates and media without phenol red. Wells were
washed once with HBSS and ﬁxed as described above, and the lower part of the insert was imaged
without removal from the plate using a Cytation3 cell imaging multimode plate reader (Bio-Tek
Instruments, Inc.).
Soft substrate preparation and microscopy. PA pads were prepared in 35-mm-diameter glass-
bottomed dishes as previously described (66), coated with 50 g/ml rat collagen, and used as the
substrates for hCMEC monolayers that reproduce the physical properties of in vivo tissues (46). For
staining of junctions, monolayers were washed with HBSS and ﬁxed either with 100% cold methanol
(for staining with anti-vascular endothelial cadherin [anti-VE-cadherin] [clone 55-7H1; BD Biosciences]) or
with 4% formaldehyde–HBSS (for staining with ZO-1 [clone 1A12; Invitrogen] or with claudin-5 [clone
4C3C2; Invitrogen]; not shown). The dishes were then either incubated for 6 h, washed, and processed
for TEM or placed into an environmental chamber (Stage Top incubator; Tokai Hit, Shizuokaken, Japan)
at 37°C and 5% CO2 on an inverted microscope (Olympus IX72) for video recording, with images (DIC
[differential inference contrast], ﬂuorescein isothiocyanate [FITC], and Texas Red channels) captured
every minute for 6 to 16 h.
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